Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells

European Journal of Pharmacology

Volumn 627, Issue 1-3, 2010, Pages 348-353

  Tatsuda, Yoshiki ^a   Iguchi, Kazuhiro ^a   Usui, Shigeyuki ^a   Suzui, Masumi ^a   Hirano, Kazuyuki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Pamidronate; Prostate cancer; Protein kinase C; uPA

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALPHOSTIN C; ETIDRONIC ACID; MEVALONIC ACID; NITROGEN; PAMIDRONIC ACID; PROTEIN KINASE C; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C ALPHA; PROTEIN KINASE C THETA; RISEDRONIC ACID; STAUROSPORINE; UROKINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; DIPHOSPHONATES; ENZYME STABILITY; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PROTEIN PRENYLATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 73449085486     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.067     Document Type: Article

References (45)

1. Advani R., Peethambaram P., Lum B.L., Fisher G.A., Hartmann L., Long H.J., Halsey J., Holmlund J.T., Dorr A., and Sikic B.I. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase Cα, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100 (2004) 321-326
2. Asahi H., Mizokami A., Miwa S., Keller E.T., Koshida K., and Namiki M. Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. Int. J. Urol. 13 (2006) 593-600
3. Balendran A., Hare G.R., Kieloch A., Williams M.R., and Alessi D.R. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett. 484 (2000) 217-223
4. Benasciutti E., Pagès G., Kenzior O., Folk W., Blasi F., and Crippa M.P. MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 104 (2004) 256-262
5. Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., Delmas P., Delaisse J.M., and Clezardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60 (2000) 2949-2954
6. Cai H., Smola U., Wixler V., Eisenmann-Tappe I., Diaz-Meco M.T., Moscat J., Rapp U., and Cooper G.M. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol. Cell. Biol. 17 (1997) 732-741
7. Castagna M., Takai Y., Kaibuchi K., Sano K., Kikkawa U., and Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257 (1982) 7847-7851
8. Cornford P., Evans J., Dodson A., Parsons K., Woolfenden A., Neoptolemos J., and Foster C.S. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am. J. Pathol. 154 (1999) 137-144
9. Fleisch H. Bisphosphonates: mechanisms of action. Endocr. Rev. 19 (1998) 80-100
10. Fleisch H. Development of bisphosphonates. Breast Cancer Res. 4 (2002) 30-34
11. Fleisch H., Russell R.G., and Francis M.D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165 (1969) 1262-1264
12. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., Jakesz R., Seifert M., Hubalek M., Bjelic-Radisic V., Samonigg H., Tausch C., Eidtmann H., Steger G., Kwasny W., Dubsky P., Fridrik M., Fitzal F., Stierer M., Rucklinger E., Greil R., and Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360 (2009) 679-691
13. Hashizume H., Kamio N., Nakao S., Matsushima K., and Sugiya H. Protein kinase C synergistically stimulates tumor necrosis factor-α-induced secretion of urokinase-type plasminogen activator in human dental pulp cells. J. Physiol. Sci. 58 (2008) 83-86
14. Iguchi K., Hirano K., Hamatake M., and Ishida R. Phosphatidylserine induces apoptosis in adherent cells. Apoptosis 6 (2001) 263-268
15. Iguchi K., Matsunaga S., Nakano T., Usui S., and Hirano K. Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells. Anticancer Res. 26 (2006) 2977-2981
16. Iguchi K., Nakano T., Usui S., and Hirano K. Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells. Cancer Lett. 237 (2006) 223-233
17. Iguchi K., Tatsuda Y., Usui S., and Hirano K. Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells. Anticancer Res. 27 (2007) 3843-3848
18. Lahn M., Sundell K., Gleave M., Ladan F., Su C., Li S., Ma D., Paterson B.M., and Bumol T.F. Protein kinase C-α in prostate cancer. BJU Int. 93 (2004) 1076-1081
19. Lee M.V., Fong E.M., Singer F.R., and Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61 (2001) 2602-2608
20. Mackay H.J., and Twelves C.J. Targeting the protein kinase C family: are we there yet?. Nat. Rev. Cancer 7 (2007) 554-562
21. Marshall C.J. Cell signalling. Raf gets it together. Nature 383 (1996) 127-128
22. Matsunaga S., Iguchi K., Usui S., and Hirano K. Incadronate induces cell detachment and apoptosis in prostatic PC-3 cells. Anticancer Res. 27 (2007) 927-932
23. Nakashima S. Protein kinase Cα (PKCα): regulation and biological function. J. Biol. Chem. 132 (2002) 669-675
24. Nishida S., Fujii Y., Yoshioka S., Kikuichi S., Tsubaki M., and Irimajiri K. A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sci. 73 (2003) 2655-2664
25. Oades G.M., Senaratne S.G., Clarke I.A., Kirby R.S., and Colston K.W. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J. Urol. 170 (2003) 246-252
26. Paz-Ares L., Douillard J.Y., Koralewski P., Manegold C., Smit E.F., Reyes J.M., Chang G.C., John W.J., Peterson P.M., Obasaju C.K., Lahn M., and Gandara D.R. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 24 (2006) 1428-1434
27. Powell C.T., Brittis N.J., Stec D., Hug H., Heston W.D., and Fair W.R. Persistent membrane translocation of protein kinase C α during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ. 7 (1996) 419-428
28. Pulukuri S.M., Gondi C.S., Lakka S.S., Jutla A., Estes N., Gujrati M., and Rao J.S. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 280 (2005) 36529-36540
29. Reszka A.A., Halasy-Nagy J., and Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol. Pharmacol. 59 (2001) 193-202
30. Ritch P., Rudin C.M., Bitran J.D., Edelman M.J., Makalinao A., Irwin D., Lilenbaum R., Peterson P., and John W.J. Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 52 (2006) 173-180
31. Russell R.G., Xia Z., Dunford J.E., Oppermann U., Kwaasi A., Hulley P.A., Kavanagh K.L., Triffitt J.T., Lundy M.W., Phipps R.J., Barnett B.L., Coxon F.P., Rogers M.J., Watts N.B., and Ebetino F.H. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. N. Y. Acad. Sci. 1117 (2007) 209-257
32. Ruvolo P.P., Deng X., Carr B.K., and May W.S. A functional role for mitochondrial protein kinase Cα in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 273 (1998) 25436-25442
33. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., Golub E., and Rodan G.A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88 (1991) 2095-2105
34. Sawada K., Morishige K., Tahara M., Kawagishi R., Ikebuchi Y., Tasaka K., and Murata Y. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res. 62 (2002) 6015-6020
35. Schweinitz A., Steinmetzer T., Banke I.J., Arlt M.J., Sturzebecher A., Schuster O., Geissler A., Giersiefen H., Zeslawska E., Jacob U., Kruger A., and Sturzebecher J. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J. Biol. Chem. 279 (2004) 33613-33622
36. Sheng S. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev. 20 (2001) 287-296
37. Shukla S., Maclennan G.T., Hartman D.J., Fu P., Resnick M.I., and Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int. J. Cancer 121 (2007) 1424-1432
38. Sliva D., English D., Lyons D., and Lloyd Jr. F.P. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-κB. Biochem. Biophys. Res. Commun. 290 (2002) 552-557
39. Smith M.R., McGovern F.J., Zietman A.L., Fallon M.A., Hayden D.L., Schoenfeld D.A., Kantoff P.W., and Finkelstein J.S. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345 (2001) 948-955
40. Ueda Y., Hirai S., Osada S., Suzuki A., Mizuno K., and Ohno S. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J. Biol. Chem. 271 (1996) 23512-23519
41. Valenti M.T., Bertoldo F., Dalle Carbonare L., Azzarello G., Zenari S., Zanatta M., Balducci E., Vinante O., and Lo Cascio V. The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?. BMC Cancer 6 (2006) 49
42. Villar J., Quadri H.S., Song I., Tomita Y., Tirado O.M., and Notario V. PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Cα-mediated Bcl-2 stabilization. Cancer Res. 69 (2009) 102-110
43. Virtanen S.S., Vaananen H.K., Harkonen P.L., and Lakkakorpi P.T. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. 62 (2002) 2708-2714
44. Walker K., and Olson M.F. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin. Genet. Dev. 15 (2005) 62-68
45. Yasuda I., Kishimoto A., Tanaka S., Tominaga M., Sakurai A., and Nishizuka Y. A synthetic peptide substrate for selective assay of protein kinase C. Biochem. Biophys. Res. Commun. 166 (1990) 1220-1227